PRG3 induces Ras-dependent oncogenic cooperation in gliomas

Supplementary Materials

	10	TM1 ²⁰	30	40	50	60
hPRG-3	MAVGNNTQRS	YSIIPCFIFV	ELVIMAGTVL	LAYYFECTDT	FQVHIQGFFC	QDGDLMKPYP
mPRG-3	MAVENNTQRS	YSIIPCFIFV	ELVIMAGTVL	LAYYFECTDT	FQVHIQGFFC	QDGDLMKPYP
rPRG-3	MAVENNTORS	YSIIPCFIFV	ELVIMAGTVL	LAYYFECTDT	FQVHIQGFFC	QDGDLMKPYP
	TM2 ⁷⁰	80	90	100	110	120
hPRG-3	GTEEESFITP	LVLYCVLAAT	PTAIIFIGEI	SMYFIKSTRE	SLIAQEKTIL	TGECCYLNPL
mPRG-3	GTEEESFISP	LVLYCVLAAT	PTAIIFIGEI	SMYFIKSTRE	SLIAEEKMIL	TGDCCYLSPL
rPRG-3	GTEEESFI SP	LVLYCVLAAT	PTAIIFIGEI	SMYFIKSTRE	SLIAEEKMIL	TGDCCYLSPL
	тмз ¹³⁰	140	150	160	170	180
hPRG-3	LRRIIRFTGV	FAFGLFATDI	FVNAGQVVTG	HLTPYFLTVC	KPNYTSADCQ	AHHQFINNGN
mPRG-3	LRRIIRFIGV	FAFGLFATDI	FVNAGQVVTG	HLTPYFLTVC	QPNYTSTDCR	AHQQFINNGN
rPRG-3	LRRIVRFIGV	FAFGLFATDI	FVNAGQVVTG	HLTPYFLTVC	QPNYTSTDCR	AHHQFINNGN
	190	200	TM4 210	220	230	M5 240
hPRG-3	190 ICTGDLEVIE	200 KARRSFPSKH	TM4 210 AALSIYSALY	220 ATMYITSTIK	230 TKSSRLAKPV	M5 240 LCLGTLCTAF
hPRG-3 mPRG-3	190 ICTGDLEVIE ICTGDLEVIE	200 KARRSFPSKH KARRSFPSKH	TM4 210 AALSIYSALY AALSIYSALY	220 ATMYITSTIK ATMYITSTIK	230 TKSSRLAKPV TKSSRLAKPV	M5 240 LCLGTLCTAF LCLGTLCTAF
hPRG-3 mPRG-3 rPRG-3	190 ICTGDLEVIE ICTGDLEVIE ICTGDLEVIE	200 KARRSFPSKH KARRSFPSKH KARRSFPSKH	TM4 210 AALSIYSALY AALSIYSALY AALSIYSALY	220 ATMYITSTIK ATMYITSTIK ATMYITSTIK	TKSSRLAKPV TKSSRLAKPV TKSSRLAKPV	M5 240 LCLGTLCTAF LCLGTLCTAF LCLGDLCTAF
hPRG-3 mPRG-3 rPRG-3	190 ICTGDLEVIE ICTGDLEVIE ICTGDLEVIE 250	200 KARRSFPSKH KARRSFPSKH KARRSFPSKH	TM4 210 AALSIYSALY AALSIYSALY AALSIYSALY 270	220 ATMYITSTIK ATMYITSTIK ATMYITSTIK 280	230 TKSSRLAKPV TKSSRLAKPV TKSSRLAKPV 290	M5 240 LCLGTLCTAF LCLGTLCTAF LCLGDLCTAF 300
hPRG-3 mPRG-3 rPRG-3 hPRG-3	190 ICTGDLEVIE ICTGDLEVIE 250 LTGLNRVSEY	200 KARRSFPSKH KARRSFPSKH KARRSFPSKH ^{TM6²⁶⁰ RNHCSDVIAG}	TM4 210 AALSIYSALY AALSIYSALY AALSIYSALY 270 FILGTAVALF	220 ATMYITSTIK ATMYITSTIK ATMYITSTIK 280 LGMCVVHNFK	230 TKSSRLAKPV TKSSRLAKPV TKSSRLAKPV 290 GTQGSPSKPK	M5 240 LCLGTLCTAF LCLGTLCTAF LCLGDLCTAF 300 PEDPRGVPLM
hPRG-3 mPRG-3 rPRG-3 hPRG-3 mPRG-3	190 ICTGDLEVIE ICTGDLEVIE ICTGDLEVIE 250 LTGLNRVSEY LTGLNRVSEY	200 KARRSFPSKH KARRSFPSKH KARRSFPSKH M6 ²⁶⁰ RNHCSDVIAG RNHCSDVIAG	M4 210 AALSIYSALY AALSIYSALY AALSIYSALY 270 FILGTAVALF FILGTAVALF	220 ATMYITSTIK ATMYITSTIK ATMYITSTIK 280 LGMCVVHNFK LGMCVVHNFR	230 TKSSRLAKPV TKSSRLAKPV TKSSRLAKPV 290 GTQGSPSKPK GTQGSPSKPK	M5 240 LCLGTLCTAF LCLGTLCTAF LCLGDLCTAF 300 PEDPRGVPLM PEDPRGVPLM
hPRG-3 mPRG-3 rPRG-3 hPRG-3 mPRG-3 rPRG-3	190 ICTGDLEVIE ICTGDLEVIE 250 LTGLNRVSEY LTGLNRVSEY LTGLNRVSEY	200 KARRSFPSKH KARRSFPSKH KARRSFPSKH MARSFPSKH MACSDVIAG RNHCSDVIAG RNHCSDVIAG	M4 210 AALSIYSALY AALSIYSALY AALSIYSALY 270 FILGTAVALF FILGTAVALF	220 ATMYITSTIK ATMYITSTIK 280 LGMCVVHNFK LGMCVVHNFR LGMCVVHNFK	230 TKSSRLAKPV TKSSRLAKPV TKSSRLAKPV 290 GTQGSPSKPK GTQGSPSKPK GTQGSPSKPK	LCLGTLCTAF LCLGTLCTAF LCLGDLCTAF 300 PEDPRGVPLM PEDPRGVPLM PEDPRGVPLM
hPRG-3 mPRG-3 rPRG-3 hPRG-3 mPRG-3 rPRG-3	190 ICTGDLEVIE ICTGDLEVIE 250 ITGLNRVSEY ITGLNRVSEY ITGLNRVSEY 310	200 KARRSFPSKH KARRSFPSKH KARRSFPSKH CONTAG RNHCSDVIAG RNHCSDVIAG RNHCSDVIAG RNHCSDVIAG 320	AALSIYSALY AALSIYSALY AALSIYSALY 270 FILGTAVALF FILGTAVALF FILGTAVALF 330	220 ATMYITSTIK ATMYITSTIK 280 LGMCVVHNFK LGMCVVHNFR LGMCVVHNFR	230 TKSSRLAKPV TKSSRLAKPV 290 GTQGSPSKPK GTQGSPSKPK GTQGSASKPK	LCLGTLCTAF LCLGTLCTAF LCLGDLCTAF 300 PEDPRGVPLM PEDPRGVPLM PEDPRGVPLM
hPRG-3 mPRG-3 rPRG-3 hPRG-3 mPRG-3 rPRG-3 hPRG-3	190 ICTGDLEVIE ICTGDLEVIE 250 LTGLNRVSEY LTGLNRVSEY LTGLNRVSEY 310 AFPRIESPLE	200 KARRSFPSKH KARRSFPSKH KARRSFPSKH CONTENSIONAL RNHCSDVLAG RNHCSDVLAG RNHCSDVLAG 200 320 TLSAQNHSAS	M4 210 AALSIYSALY AALSIYSALY AALSIYSALY 270 FILGTAVALF FILGTAVALF FILGTAVALF 330 MTEVT	220 ATMYITSTIK ATMYITSTIK 280 LGMCVVHNFK LGMCVVHNFR LGMCVVHNFK	230 TKSSRLAKPV TKSSRLAKPV 290 GTQGSPSKPK GTQGSPSKPK GTQGSASKPK	M5 240 LCLGTLCTAF LCLGTLCTAF LCLGDLCTAF 300 PEDPRGVPLM PEDPRGVPLM PEDPRGVPLM
hPRG-3 mPRG-3 rPRG-3 mPRG-3 rPRG-3 hPRG-3 mPRG-3	190 ICTGDLEVIE ICTGDLEVIE 250 ITGLNRVSEY ITGLNRVSEY ITGLNRVSEY 310 AFPRIESPLE AFPRIESPLE	200 KARRSFPSKH KARRSFPSKH KARRSFPSKH MARSFPSKH MACSDVIAG RNHCSDVIAG RNHCSDVIAG RNHCSDVIAG 320 TLSAQNHSAS	MALSIYSALY AALSIYSALY AALSIYSALY AALSIYSALY FILGTAVALF FILGTAVALF FILGTAVALF 3330 MTEVT *	220 ATMYITSTIK ATMYITSTIK 280 LGMCVVHNFK LGMCVVHNFR LGMCVVHNFR	230 TKSSRLAKPV TKSSRLAKPV 290 GTQGSPSKPK GTQGSPSKPK GTQGSASKPK	LCLGTLCTAF LCLGTLCTAF LCLGDLCTAF 300 PEDPRGVPLM PEDPRGVPLM PEDPRGVPLM

Supplementary Figure S1: PRG3 amino acid sequence alignment of human, rat and mouse species. Amino acid sequence of human PRG3 (GenBank Accession no. AY337718) aligned to mouse PRG3 (GenBank Accession no. AY345342) and rat PRG3 (GenBank Accession no. AY299399). Putative transmembrane domains TM1 - TM6 are boxed (black lines).



Supplementary Figure S2: PRG3 expression enhances human tumor proliferation. (A) PRG3 boosts growth in human glioma cells. Quantitative growth analysis of human glioma cells (U87) over time. Note that PRG3 overexpressing cells grow significantly faster than wild-type (WT) gliomas. Statistical significance was calculated with Student's *t*-test (mean \pm SD, n > 12 per group; *P < 0.05). (B) PRG3 boosts growth in murine glioma cells. Quantitative analysis of cell growth in murine glioma cells (GL-261) over time. Note that PRG3 overexpressing cells grow significantly faster than RFP control transfected cells. Statistical significance was calculated with Student's *t*-test (mean \pm SD, n = 12 per group; *P < 0.05). Abbreviation: OD, optical density.



Supplementary Figure S3: (A) *Left*, **Perturbed PRG3 expression leads to elevated Ras activation.** Upper blot gives levels of activated GTP-Ras in wild-type (WT), PRG3 overexpressing (PRG3) and PRG3-knockdown (PRG3^{kd}) gliomas. Total Ras served as controls for equal loading (bottom panel). *Right*, C-terminal tail deleted PRG3 construct does not affect Ras signaling. **(B)** PRG3 promotes cell growth through its C-terminal domain. Quantitative analysis of cell growth over time of parental (WT) and PRG3-C-terminal domain expressing (PRG3^{CT}) glioma cells. Statistical significance was calculated with Student's *t*-test (mean \pm SD, *n* = 4 per group; **P* < 0.005). **(C)** PRG3^{CT} expression in gliomas alters cellular morphology and activates Ras. *Left*, representative images showed PRG3-C-terminal domain expressing (PRG3^{CT}) glioma cells exert an elongated cell shapes comparable to PRG3 full length expressing gliomas. Middle, Upper blot shows PRG3^{CT} expression levels in wild-type (WT) and PRG3^{CT} glioma cells. Total Ras served as a control for equal loading (bottom panel). *Right*, Upper panel shows activated Ras-GTP in wild-type (WT) and PRG3^{CT} glioma cells. Total Ras served as a control for equal loading (bottom panel). Scale bar represents 50 µm.



Supplementary Figure S4: The C-terminal domain of PRG3 promotes oncogenesis and glioma growth. Oncogenic amplification of glioma cells after expression of the C-terminal domain of PRG3. (A) Quantitative analysis of colony formation in parental wild-type glioma cells (WT) and PRG3 C-terminal domain expressing gliomas (PRG3^{CT}). Quantification is given from three independent experiments. Values are given as mean \pm SD, **P* < 0.001 (Student's unpaired *t*-test). (B) Representative images of colonies formed in soft agar from wild-type glioma cells (WT) and PRG3 C-terminus expressing gliomas (PRG3^{CT}). Scale bar, 500 µm. (C) Expression of PRG3 C-terminal domain expressing gliomas (PRG3^{CT}). Scale bar, 500 µm. (C) Expression of PRG3 C-terminal domain expressing gliomas (PRG3^{CT}) fosters tumor expansion into brain parenchyma. GFP+ glioma cells (WT) and PRG3 C-terminal domain expressing gliomas (PRG3^{CT}) were implanted in brain slices and tumor expansion was evaluated after various days. Quantitative analysis of tumor expansion (bright colored columns represent tumor expansion at day 1; faintly colored columns represent tumor expansion at day 7). Statistical significance was calculated with Student's unpaired *t*-test (mean \pm SD, *n* = 6 per group; **P* < 0.005).